Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free POLB Stock Alerts

Poolbeg Pharma (POLB) Competitors

Poolbeg Pharma logo
GBX 8.40 -0.14 (-1.62%)
As of 08:39 AM Eastern
Compare

POLB vs. ARIX, CIR, TILS, VSN, and SCLP

Should you buy Poolbeg Pharma stock or one of its competitors? Poolbeg Pharma's main competitors and comparable companies include Arix Bioscience (ARIX), Circassia Group (CIR), Tiziana Life Sciences (TILS), Verseon (VSN), and Scancell (SCLP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Poolbeg Pharma compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and Poolbeg Pharma (LON:POLB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

In the previous week, Arix Bioscience's average media sentiment score of 0.00 equaled Poolbeg Pharma'saverage media sentiment score.

Company Overall Sentiment
Arix Bioscience Neutral
Poolbeg Pharma Neutral

Arix Bioscience has a net margin of 105.64% compared to Poolbeg Pharma's net margin of 0.00%. Arix Bioscience's return on equity of 6.41% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Arix Bioscience105.64% 6.41% 2.18%
Poolbeg Pharma N/A -55.47%-21.33%

Arix Bioscience has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arix Bioscience£14.16M0.00£14.96M£0.11N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

41.3% of Arix Bioscience shares are owned by institutional investors. Comparatively, 1.5% of Poolbeg Pharma shares are owned by institutional investors. 20.7% of Arix Bioscience shares are owned by company insiders. Comparatively, 7.5% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Arix Bioscience has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Poolbeg Pharma has a beta of 1.802, indicating that its share price is 80% more volatile than the broader market.

Summary

Arix Bioscience beats Poolbeg Pharma on 9 of the 10 factors compared between the two stocks.

How does Poolbeg Pharma compare to Circassia Group?

Poolbeg Pharma (LON:POLB) and Circassia Group (LON:CIR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Circassia Group's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -55.47% -21.33%
Circassia Group N/A N/A N/A

1.5% of Poolbeg Pharma shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Circassia Group has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A
Circassia Group£27.90M0.00N/A£0.01N/A

In the previous week, Poolbeg Pharma's average media sentiment score of 0.00 equaled Circassia Group'saverage media sentiment score.

Company Overall Sentiment
Poolbeg Pharma Neutral
Circassia Group Neutral

Summary

Circassia Group beats Poolbeg Pharma on 5 of the 7 factors compared between the two stocks.

How does Poolbeg Pharma compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and Poolbeg Pharma (LON:POLB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

1.5% of Poolbeg Pharma shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Tiziana Life Sciences' average media sentiment score of 0.00 equaled Poolbeg Pharma'saverage media sentiment score.

Company Overall Sentiment
Tiziana Life Sciences Neutral
Poolbeg Pharma Neutral

Tiziana Life Sciences' return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Tiziana Life SciencesN/A N/A N/A
Poolbeg Pharma N/A -55.47%-21.33%

Tiziana Life Sciences has higher earnings, but lower revenue than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

Summary

Poolbeg Pharma beats Tiziana Life Sciences on 4 of the 7 factors compared between the two stocks.

How does Poolbeg Pharma compare to Verseon?

Poolbeg Pharma (LON:POLB) and Verseon (LON:VSN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A
VerseonN/AN/AN/A-£14.30N/A

In the previous week, Poolbeg Pharma's average media sentiment score of 0.00 equaled Verseon'saverage media sentiment score.

Company Overall Sentiment
Poolbeg Pharma Neutral
Verseon Neutral

Verseon's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -55.47% -21.33%
Verseon N/A N/A N/A

1.5% of Poolbeg Pharma shares are owned by institutional investors. 7.5% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Poolbeg Pharma and Verseon tied by winning 3 of the 6 factors compared between the two stocks.

How does Poolbeg Pharma compare to Scancell?

Poolbeg Pharma (LON:POLB) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Poolbeg Pharma has a beta of 1.802, suggesting that its stock price is 80% more volatile than the broader market. Comparatively, Scancell has a beta of 0.687, suggesting that its stock price is 31% less volatile than the broader market.

1.5% of Poolbeg Pharma shares are owned by institutional investors. Comparatively, 1.5% of Scancell shares are owned by institutional investors. 7.5% of Poolbeg Pharma shares are owned by insiders. Comparatively, 15.5% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Scancell has higher revenue and earnings than Poolbeg Pharma. Scancell is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A
Scancell£4.71M21.37-£6.75M-£0.55N/A

In the previous week, Scancell had 1 more articles in the media than Poolbeg Pharma. MarketBeat recorded 1 mentions for Scancell and 0 mentions for Poolbeg Pharma. Poolbeg Pharma's average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score.

Company Overall Sentiment
Poolbeg Pharma Neutral
Scancell Neutral

Poolbeg Pharma has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -55.47% -21.33%
Scancell -116.98%90.29%-45.28%

Summary

Scancell beats Poolbeg Pharma on 6 of the 11 factors compared between the two stocks.

Get Poolbeg Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

POLB vs. The Competition

Export
MetricPoolbeg PharmaBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£64.13M£3.94B£7.20B£2.89B
Dividend YieldN/A3.61%2.54%6.17%
P/E Ratio-8.9411.63272.60367.23
Price / SalesN/A1,344.83625.2583,303.72
Price / Cash2.1144.0628.7427.89
Price / Book0.0016.8911.086.94
Net Income-£4.50B-£22.72M£3.47B£5.89B
7 Day Performance-2.20%0.98%0.14%0.47%
1 Month Performance25.37%13.03%8.16%3.60%
1 Year Performance163.08%54.89%24.13%22.41%

Poolbeg Pharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
POLB
Poolbeg Pharma
N/AGBX 8.40
-1.6%		N/A+163.8%£64.13MN/AN/A12
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11
VSN
Verseon
N/AN/AN/AN/A£112.24MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:POLB) was last updated on 9/1/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel